The company said, “For the full-year 2025 outlook, sales growth is now expected to be 8-11% at CER with operating profit growth now expected to be 4-7% also at CER, including a negative full-year impact of around DKK 8 billion from the company-wide transformation. Sales and operating profit growth reported in Danish kroner is now expected to be 4 and 6 percentage points lower than at CER, respectively. The narrowing of the guidance ranges reflects lowered growth expectations for Novo Nordisk’s (NVO) GLP-1 treatments within diabetes and obesity.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- These Are the Stocks Reporting Earnings Today – November 5, 2025
- Trump in talks with Lilly, Novo on weight loss drug deal, WSJ says
- Hims & Hers Stock (HIMS) Soars on Potential Deal to Offer Novo Nordisk’s Wegovy
- M&A News: Novo Nordisk Stock (NVO) Slides after Increasing Its Metsera Offer to $10B
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV